Literature DB >> 11109883

[Parathyroid carcinoma: diagnosis and treatment].

L Castillo1, G Poissonnet, A Haddad, N Guevara, J Santini, F Demard.   

Abstract

Pre operative and per-operative suspicion, and recognition of parathyroid carcinoma are essential in the effective approach and the prognosis of this type of tumor. On the basis of our experience over 20 years, helped by the literature we review our 179 cases of primary hyperparathyroidism out of which 5 were malignant tumors and the 174 others were benign (adenomas and hyperplasias). We conclude that patients with primary hyperparathyroidism, reflected by high levels of serum calcium (75%) and elevated levels of parathormone (100%) are suspect of carrying a parathyroid malignancy particularly when these levels are profoundly abnormal. Furthermore, a severe clinical presentation featuring, palpable cervical mass, renal symptoms in 30% to 60% of all, bone disease in 90%, is suspect of malignancy. The operative findings such as important size of tumour, local seeding, local invasion are also significant features of malignancy. All this data gathered by comparing carcinomas to adenomas suggest and confirm what many reviews on the subject have reported, early recognition of the parathyroid carcinoma is of primal importance, because aggressive initial surgical management should be applied, as total extirpation of the malignancy is the only treatment allowing maximal survival rates.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11109883

Source DB:  PubMed          Journal:  Rev Laryngol Otol Rhinol (Bord)        ISSN: 0035-1334


  2 in total

1.  Huge parathyroid carcinoma: clinical considerations and literature review.

Authors:  Maria Grazia Chiofalo; Francesco Scognamiglio; Simona Losito; Secondo Lastoria; Ugo Marone; Luciano Pezzullo
Journal:  World J Surg Oncol       Date:  2005-06-23       Impact factor: 2.754

2.  Four ultrasound and clinical pictures of parathyroid carcinoma.

Authors:  Milan Halenka; David Karasek; Zdenek Frysak
Journal:  Case Rep Endocrinol       Date:  2012-11-14
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.